#Israel #Caesarea #IceCure Medical #Cryoablation #ProSense

IceCure Medical's Preliminary Financial Results for Q2 2025

IceCure Medical Ltd. (Nasdaq: ICCM), a leading innovator in minimally-invasive cryoablation technology, has disclosed its preliminary financial results for the second quarter of 2025, ending June 30. The company is known for its advanced therapies that destroy tumors by freezing, providing a less invasive alternative to traditional surgical methods.

Financial Highlights

For the three months concluded on June 30, 2025, IceCure reported an expected product sale of approximately $525,000. However, the company faced some challenges during the quarter due to delivery delays for non-U.S. shipments attributed to geopolitical tensions, notably between Israel and Iran. Nonetheless, the order flow itself was not severely impacted. The delayed shipments are set to resume, and it is anticipated that over $200,000 worth of product sales, initially scheduled for the second quarter, will be recognized in July 2025.

As a result of the aforementioned delays, total product sales for the first six months of 2025 came in at approximately $1.25 million. This figure is a noticeable drop from the $1.65 million recorded during the same period in 2024. It's worth noting that last year's results included $100,000 in revenue from an exclusive distribution agreement with Terumo in Japan, marking a slightly varied financial landscape this year.

Impact of Inventory on U.S. Market

Despite the delay in international shipments, IceCure’s operations in the U.S. remained steady, buffered by adequate inventory levels of ProSense® systems and probes held nationwide. This inventory management strategy has proven effective in shielding the U.S. market from any disruptions caused by temporary shipment delays.

The financial report highlighted the variability in IceCure's sales patterns, wherein fluctuations quarter-over-quarter are a possibility due to the nature of customer orders and shipments.

Future Financial Reporting

IceCure plans to unveil its comprehensive financial results for the second quarter and first half of 2025 in August 2025. Notably, the company clarified that it doesn’t intend to issue preliminary financial results quarterly unless absolutely necessary.

A Note on Preliminary Estimates

The preliminary financial information provided is based on the best estimates available to IceCure’s management and should not be interpreted as a finalized statement of revenue for the period mentioned. The results are subject to final adjustments and internal reviews, and the independent registered public accounting firm of IceCure has neither audited nor expressed an opinion on this data.

About IceCure Medical

IceCure Medical, listed on Nasdaq under the ticker ICCM, specializes in the development of liquid-nitrogen-based cryoablation systems that effectively target benign and malignant tumors across various body regions, including the breast, kidney, bone, and lung. The flagship ProSense® system is marketed across global markets and boasts a strong compliance history with medical regulations in the U.S., Europe, and Asia.

Looking Ahead

The financial performance metrics outlined in this report attempt to capture IceCure’s ongoing trends, but external variables such as changes in the geopolitical landscape or internal shifts in production and marketing strategies will undoubtedly play a role in shaping future results. Investors and industry stakeholders will be keenly watching the forthcoming comprehensive results for a better understanding of IceCure's resilience and market adaptability.

• ---